2026-06-14T05:05:21Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/84962024-11-29T16:40:23Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Barrero, Maria Jose author 2017-05-23 Recently, immunotherapeutic approaches have shown impressive responses in a subset of cancer patients. However, the rate of success is low and a large percentage of treated patients do not experience clinical benefits. Therefore, additional strategies are needed to improve responses and select responsive patients. Emerging data suggest that epigenetic drugs can improve the responses to immunotherapy. Understanding the mechanisms of resistance to immunotherapy and the epigenetic events that take place during immune evasion is critical to providing a rational combined use of immunotherapies and epigenetic drugs. This review focuses in the epigenetic mechanisms involved in the responses to immunotherapy and how current drugs that target epigenetic regulators impact on them. Int J Mol Sci. 2017;18(6). pii: E1108. 10.3390/ijms18061108 1422-0067 1422-0067 International journal of molecular sciences 28545238 http://hdl.handle.net/20.500.12105/8496 cancer epigenetics immunotherapy Epigenetic Strategies to Boost Cancer Immunotherapies